Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone353-1485-1200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$103.27 million
Profitability
Miscellaneous
Employees144
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions
What is Avadel Pharmaceuticals' stock symbol?
Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."
How will Avadel Pharmaceuticals' stock buyback program work?
Avadel Pharmaceuticals announced that its board has initiated a share repurchase program on Wednesday, March 28th 2018, which allows the company to buyback $7,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 2.7% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board believes its shares are undervalued.
How were Avadel Pharmaceuticals' earnings last quarter?
Avadel Pharmaceuticals PLC (NASDAQ:AVDL) posted its quarterly earnings data on Friday, August, 9th. The company reported ($0.23) EPS for the quarter. The company earned $17.55 million during the quarter. Avadel Pharmaceuticals had a negative return on equity of 608.04% and a negative net margin of 135.48%. View Avadel Pharmaceuticals' Earnings History.
When is Avadel Pharmaceuticals' next earnings date?
What price target have analysts set for AVDL?
2 equities research analysts have issued 1-year target prices for Avadel Pharmaceuticals' stock. Their predictions range from $3.00 to $6.00. On average, they expect Avadel Pharmaceuticals' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 63.6% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals.
What is the consensus analysts' recommendation for Avadel Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avadel Pharmaceuticals.
Has Avadel Pharmaceuticals been receiving favorable news coverage?
News stories about AVDL stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a news impact score of -2.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Avadel Pharmaceuticals.
Who are some of Avadel Pharmaceuticals' key competitors?
Some companies that are related to Avadel Pharmaceuticals include Neptune Wellness Solutions (NEPT), Merus (MRUS), Karuna Therapeutics (KRTX), Provention Bio (PRVB), resTORbio (TORC), Corbus Pharmaceuticals (CRBP), MediciNova (MNOV), AC Immune (ACIU), Verrica Pharmaceuticals (VRCA), Kadmon (KDMN), Prothena (PRTA), Atreca (BCEL), Forty Seven (FTSV), DURECT (DRRX) and Ardelyx (ARDX).
What other stocks do shareholders of Avadel Pharmaceuticals own?
Who are Avadel Pharmaceuticals' key executives?
Avadel Pharmaceuticals' management team includes the folowing people:
- Mr. Michael F. Kanan, Sr. VP & CFO (Age 56)
- Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
- Mr. Gregory J. Divis, VP of Corp. and Bus. Devel. (Age 54)
- Ms. Sandra L. Hatten, Sr. VP of Quality & Regulatory Affairs (Age 62)
- Mr. Gregory J. Divis Jr., Interim Chief Exec. Officer (Age 52)
Who are Avadel Pharmaceuticals' major shareholders?
Avadel Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Brandes Investment Partners LP (18.17%), Brown Capital Management LLC (4.08%), Renaissance Technologies LLC (2.15%), Morgan Stanley (1.92%), Acadian Asset Management LLC (0.57%) and CIBC Private Wealth Group LLC (0.40%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, James E Flynn, Michael S Anderson, Peter J Thornton and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.
Which major investors are selling Avadel Pharmaceuticals stock?
Which major investors are buying Avadel Pharmaceuticals stock?
AVDL stock was purchased by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Renaissance Technologies LLC, Brown Capital Management LLC, Susquehanna International Group LLP, JPMorgan Chase & Co. and Morgan Stanley. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton, Michael S Anderson and Peter J Thornton. View Insider Buying and Selling for Avadel Pharmaceuticals.
How do I buy shares of Avadel Pharmaceuticals?
Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Avadel Pharmaceuticals' stock price today?
One share of AVDL stock can currently be purchased for approximately $2.75.
How big of a company is Avadel Pharmaceuticals?
Avadel Pharmaceuticals has a market capitalization of $102.71 million and generates $103.27 million in revenue each year. The company earns $-95,300,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.View Additional Information About Avadel Pharmaceuticals.
What is Avadel Pharmaceuticals' official website?
How can I contact Avadel Pharmaceuticals?
Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]
MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)
MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.
